EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 23-30

  Gadji, Macoura ^a   Crous, Ana Maria Tsanaclis ^a   Fortin, David ^a   Krcek, Jerry ^b   Torchia, Mark ^b   Mai, Sabine ^b,c   Drouin, Regen ^a   Klonisch, Thomas ^b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cancer stem cells; EGF receptor; GBM; Glioblastoma multiform; Glioma; Tyrosine kinase inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY L8A4; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NIMOTUZUMAB; OSI 744; PANITUMUMAB; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; MUTANT; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 71749108954     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.010     Document Type: Review

References (121)

1. Albanell J., Rojo F., and Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 28 (2001) 56-66
2. Anido J., Matar P., Albanell J., Guzman M., Rojo F., Arribas J., Averbuch S., and Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9 (2003) 1274-1283
3. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol. 30 (2003) 3-14
4. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., and Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
5. Barker II F.G., Simmons M.L., Chang S.M., Prados M.D., Larson D.A., Sneed P.K., Wara W.M., Berger M.S., Chen P., Israel M.A., and Aldape K.D. EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 410-418
6. Beier D., Rohrl S., Pillai D.R., Schwarz S., Kunz-Schughart L.A., Leukel P., Proescholdt M., Brawanski A., Bogdahn U., Trampe-Kieslich A., Giebel B., Wischhusen J., Reifenberger G., Hau P., and Beier C.P. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68 (2008) 5706-5715
7. Belda-Iniesta C., de Castro Carpeno J., Sereno M., Gonzalez-Baron M., and Perona R. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin. Transl. Oncol. 10 (2008) 73-77
8. Bigner S.H., Humphrey P.A., Wong A.J., Vogelstein B., Mark J., Friedman H.S., and Bigner D.D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50 (1990) 8017-8022
9. Broniscer A., Baker S.J., Stewart C.F., Merchant T.E., Laningham F.H., Schaiquevich P., Kocak M., Morris E.B., Endersby R., Ellison D.W., and Gajjar A. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin. Cancer Res. 15 (2009) 701-707
10. Brown P.D., Krishnan S., Sarkaria J.N., Wu W., Jaeckle K.A., Uhm J.H., Geoffroy F.J., Arusell R., Kitange G., Jenkins R.B., Kugler J.W., Morton R.F., Rowland Jr. K.M., Mischel P., Yong W.H., Scheithauer B.W., Schiff D., Giannini C., and Buckner J.C. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26 (2008) 5603-5609
11. Bruce W.R., and Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199 (1963) 79-80
12. Buckner J.C., and Moynihan T.J. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 344 686 (2001) 687-688
13. Casaco A., Lopez G., Garcia I., Rodriguez J.A., Fernandez R., Figueredo J., Torres L., Perera A., Batista J., Leyva R., Pena Y., Amador Z., Gonzalez A., Estupinan B., Coca M., Hernandez A., Puig M., Iglesias M., Ramos M., Rodriquez L., and Suarez N. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 7 (2008) 333-339
14. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., and Loeffler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 62 (2002) 4307-4315
15. Choe G., Horvath S., Cloughesy T.F., Crosby K., Seligson D., Palotie A., Inge L., Smith B.L., Sawyers C.L., and Mischel P.S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63 (2003) 2742-2746
16. Ciardiello F., Caputo R., Damiano V., Troiani T., Vitagliano D., Carlomagno F., Veneziani B.M., Fontanini G., Bianco A.R., and Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 9 (2003) 1546-1556
17. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., and Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66 (2006) 9339-9344
18. Cohen K.A., Liu T., Bissonette R., Puri R.K., and Frankel A.E. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr. Pharm. Biotechnol. 4 (2003) 39-49
19. Cohenuram M., and Saif M.W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18 (2007) 7-15
20. Collins V.P. Gliomas. Cancer Surv. 32 (1998) 37-51
21. Dancey J.E., and Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark?. Lancet 362 (2003) 62-64
22. de Groot J.F., Gilbert M.R., Aldape K., Hess K.R., Hanna T.A., Ictech S., Groves M.D., Conrad C., Colman H., Puduvalli V.K., Levin V., and Yung W.K. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol. 90 (2008) 89-97
23. Dirks P.B. Brain tumor stem cells: bringing order to the chaos of brain cancer. J. Clin. Oncol. 26 (2008) 2916-2924
24. Doherty L., Gigas D.C., Kesari S., Drappatz J., Kim R., Zimmerman J., Ostrowsky L., and Wen P.Y. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 (2006) 156-158
25. Dropcho E.J., and Soong S.J. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 47 (1996) 684-690
26. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
27. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4309-4313
28. Eskens F.A., Mom C.H., Planting A.S., Gietema J.A., Amelsberg A., Huisman H., van Doorn L., Burger H., Stopfer P., Verweij J., and de Vries E.G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98 (2008) 80-85
29. Franco-Hernandez C., Martinez-Glez V., Arjona D., de Campos J.M., Isla A., Gutierrez M., Vaquero J., and Rey J.A. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors. Cancer Genet. Cytogenet. 173 (2007) 63-67
30. Frederick L., Eley G., Wang X.Y., and James C.D. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro. Oncol. 2 (2000) 159-163
31. Freeman D.J., Bush T., Ogbagabriel S., Belmontes B., Juan T., Plewa C., Van G., Johnson C., and Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol. Cancer Ther. 8 (2009) 1536-1546
32. Friedman H.S., Kerby T., and Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6 (2000) 2585-2597
33. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol. Cancer Res. 7 (2009) 989-999
34. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., Chin L., DePinho R.A., and Cavenee W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21 (2007) 2683-2710
35. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., and Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110 (2002) 763-773
36. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
37. Goudar R.K., Shi Q., Hjelmeland M.D., Keir S.T., McLendon R.E., Wikstrand C.J., Reese E.D., Conrad C.A., Traxler P., Lane H.A., Reardon D.A., Cavenee W.K., Wang X.F., Bigner D.D., Friedman H.S., and Rich J.N. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. 4 (2005) 101-112
38. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., Liewehr D.J., Steinberg S.M., Merino M.J., Rubin S.D., and Steeg P.S. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 100 (2008) 1092-1103
39. Gupta P.B., Chaffer C.L., and Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 15 (2009) 1010-1012
40. Gurney J.G., and Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr. Opin. Oncol. 13 (2001) 160-166
41. Haas-Kogan D.A., Prados M.D., Tihan T., Eberhard D.A., Jelluma N., Arvold N.D., Baumber R., Lamborn K.R., Kapadia A., Malec M., Berger M.S., and Stokoe D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97 (2005) 880-887
42. Halatsch M.E., Gehrke E., Borhani F.A., Efferth T., Werner C., Nomikos P., Schmidt U., and Buchfelder M. EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines. Anticancer Res. 23 (2003) 2315-2320
43. Halatsch M.E., Gehrke E.E., Vougioukas V.I., Botefur I.C.F.A.B., Efferth T., Gebhart E., Domhof S., Schmidt U., and Buchfelder M. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J. Neurosurg. 100 (2004) 523-533
44. Halatsch M.E., Schmidt U., Botefur I.C., Holland J.F., and Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J. Neurosurg. 92 (2000) 297-305
45. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003
46. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2 (2001) 120-129
47. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., and Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137 (2009) 1293-1307
48. Karpel-Massler G., Schmidt U., Unterberg A., and Halatsch M.E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. Mol. Cancer Res. 7 (2009) 1000-1012
49. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro. Oncol. 1 (1999) 44-51
50. Klingler-Hoffmann M., Bukczynska P., and Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int. J. Cancer 105 (2003) 331-339
51. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., and Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14 (2008) 450-460
52. Kreisl T.N., Lassman A.B., Mischel P.S., Rosen N., Scher H.I., Teruya-Feldstein J., Shaffer D., Lis E., and Abrey L.E. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 92 (2009) 99-105
53. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., and Schackert G. Long-term survival with glioblastoma multiforme. Brain 130 (2007) 2596-2606
54. Lal A., Glazer C.A., Martinson H.M., Friedman H.S., Archer G.E., Sampson J.H., and Riggins G.J. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62 (2002) 3335-3339
55. Lammerts van Bueren J.J., Bleeker W.K., Brannstrom A., von Euler A., Jansson M., Peipp M., Schneider-Merck T., Valerius T., van de Winkel J.G., and Parren P.W. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6109-6114
56. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
57. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., and Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 (1985) 144-147
58. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., and Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5 (2006) 67
59. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
60. Marie Y., Carpentier A.F., Omuro A.M., Sanson M., Thillet J., Hoang-Xuan K., and Delattre J.Y. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64 (2005) 1444-1445
61. Martinez R., Schackert H.K., Plaschke J., Baretton G., Appelt H., and Schackert G. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 66 (2004) 395-403
62. Massague J., and Pandiella A. Membrane-anchored growth factors. Annu. Rev. Biochem. 62 (1993) 515-541
63. Meira D.D., Nobrega I., de Almeida V.H., Mororo J.S., Cardoso A.M., Silva R.L., Albano R.M., and Ferreira C.G. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. Eur. J. Cancer 45 (2009) 1265-1273
64. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., and Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005) 2012-2024
65. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33 (2006) 369-385
66. Minkovsky N., and Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 9 (2008) 1336-1346
67. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., and Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55 (1995) 5536-5539
68. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., and Miller P. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57 (1997) 4838-4848
69. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., de Tribolet N., Regli L., Wick W., Kouwenhoven M.C., Hainfellner J.A., Heppner F.L., Dietrich P.Y., Zimmer Y., Cairncross J.G., Janzer R.C., Domany E., Delorenzi M., Stupp R., and Hegi M.E. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26 (2008) 3015-3024
70. Nagane M., Coufal F., Lin H., Bogler O., Cavenee W.K., and Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56 (1996) 5079-5086
71. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., Zagzag D., Fischer I., Raza S., Medabalmi P., Eagan P., and Gruber M.L. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110 (2009) 173-180
72. Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., Michotte, A., De Greve, J., 2009. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol.
73. Nicholas M.K., Lukas R.V., Jafri N.F., Faoro L., and Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res. 12 (2006) 7261-7270
74. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., and Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7727-7731
75. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M., and Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64 (2004) 6892-6899
76. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170 (2007) 1445-1453
77. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
78. Pedersen M.W., Pedersen N., Ottesen L.H., and Poulsen H.S. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br. J. Cancer 93 (2005) 915-923
79. Peeters M., Balfour J., and Arnold D. Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment. Pharmacol. Ther. (2008)
80. Piccirillo S.G., and Vescovi A.L. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found. Symp. Proc (2006) 59-81
81. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., Vaidya M.P., Arnold L.D., Doty J.L., Iwata K.K., and Morin M.J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291 (1999) 739-748
82. Prados M.D., Lamborn K.R., Chang S., Burton E., Butowski N., Malec M., Kapadia A., Rabbitt J., Page M.S., Fedoroff A., Xie D., and Kelley S.K. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro. Oncol. 8 (2006) 67-78
83. Preusser M., Gelpi E., Rottenfusser A., Dieckmann K., Widhalm G., Dietrich W., Bertalanffy A., Prayer D., Hainfellner J.A., and Marosi C. Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. J. Neurooncol. 89 (2008) 211-218
84. Prigent S.A., Nagane M., Lin H., Huvar I., Boss G.R., Feramisco J.R., Cavenee W.K., and Huang H.S. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem. 271 (1996) 25639-25645
85. Quang T.S., and Brady L.W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 972-975
86. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.R., Wang Y.F., and Wissner A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64 (2004) 3958-3965
87. Raizer J.J. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J. Neurooncol. 74 (2005) 77-86
88. Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Friedman A.H., Herndon II J.E., Marcello J., Norfleet J.A., McLendon R.E., Sampson J.H., and Friedman H.S. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. (2009)
89. Rivera F., Salcedo M., Vega N., Blanco Y., and Lopez C. Current situation of zalutumumab. Expert. Opin. Biol. Ther. 9 (2009) 667-674
90. Ropolo M., Daga A., Griffero F., Foresta M., Casartelli G., Zunino A., Poggi A., Cappelli E., Zona G., Spaziante R., Corte G., and Frosina G. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol. Cancer Res. 7 (2009) 383-392
91. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 (1995) 183-232
92. Sampson J.H., Akabani G., Archer G.E., Bigner D.D., Berger M.S., Friedman A.H., Friedman H.S., Herndon II J.E., Kunwar S., Marcus S., McLendon R.E., Paolino A., Penne K., Provenzale J., Quinn J., Reardon D.A., Rich J., Stenzel T., Tourt-Uhlig S., Wikstrand C., Wong T., Williams R., Yuan F., Zalutsky M.R., and Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65 (2003) 27-35
93. Sandstrom M., Johansson M., Bergstrom P., Bergenheim A.T., and Henriksson R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J. Neurooncol. 88 (2008) 1-9
94. Sawyers C. Targeted cancer therapy. Nature 432 (2004) 294-297
95. Schittenhelm M.M., Kollmannsberger C., Oechsle K., Harlow A., Morich J., Honecker F., Kurek R., Storkel S., Kanz L., Corless C.L., Wong K.K., Bokemeyer C., and Heinrich M.C. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol. Cancer. Ther. 8 (2009) 481-489
96. Schmiedel J., Blaukat A., Li S., Knochel T., and Ferguson K.M. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13 (2008) 365-373
97. Shackleton M., Quintana E., Fearon E.R., and Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138 (2009) 822-829
98. Shinojima N., Tada K., Shiraishi S., Kamiryo T., Kochi M., Nakamura H., Makino K., Saya H., Hirano H., Kuratsu J., Oka K., Ishimaru Y., and Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63 (2003) 6962-6970
99. Singh S.K., Clarke I.D., Hide T., and Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 23 (2004) 7267-7273
100. Smith J.S., and Jenkins R.B. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5 (2000) D213-231
101. Sulman E., Aldape K., and Colman H. Brain tumor stem cells. Curr. Probl. Cancer 32 (2008) 124-142
102. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5 (2007) 203-220
103. Takasu S., Takahashi T., Okamoto S., Oriuchi N., Nakayashiki N., Okamoto K., Muramatsu H., Hayashi T., Nakahara N., Mizuno M., Wakabayashi T., Higuchi T., Endo K., Kozaki K., Miyaishi O., Saga S., Ueda R., Yoshida J., and Yoshikawa K. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99 m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J. Neurooncol. 63 (2003) 247-256
104. Talavera A., Friemann R., Gomez-Puerta S., Martinez-Fleites C., Garrido G., Rabasa A., Lopez-Requena A., Pupo A., Johansen R.F., Sanchez O., Krengel U., and Moreno E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. (2009)
105. Torres L.A., Perera A., Batista J.F., Hernandez A., Crombet T., Ramos M., Neninger E., Perez M., Sanchez E.L., Romero S., Aguilar V., Coca M.A., and Iznaga-Escobar N. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl. Med. Commun. 26 (2005) 1049-1057
106. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H.A., McSheehy P., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., and Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64 (2004) 4931-4941
107. von Deimling A., Louis D.N., and Wiestler O.D. Molecular pathways in the formation of gliomas. Glia 15 (1995) 328-338
108. von Deimling A., von Ammon K., Schoenfeld D., Wiestler O.D., Seizinger B.R., and Louis D.N. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3 (1993) 19-26
109. Ward C.W., Lawrence M.C., Streltsov V.A., Adams T.E., and McKern N.M. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. Trends Biochem. Sci. 32 (2007) 129-137
110. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., and Hung M.C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13 (2008) 385-393
111. Weil R.J. Incorporating molecular tools into early-stage clinical trials. PLoS Med 5 (2008) e21
112. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 66 (2006) 1883-1890 discussion 1895-1886
113. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., and Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2965-2969
114. Yamazaki H., Kijima H., Ohnishi Y., Abe Y., Oshika Y., Tsuchida T., Tokunaga T., Tsugu A., Ueyama Y., Tamaoki N., and Nakamura M. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer. Inst. 90 (1998) 581-587
115. Yamazaki H., Ohba Y., Tamaoki N., and Shibuya M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. 81 (1990) 773-779
116. Yang W., Barth R.F., Wu G., Tjarks W., Binns P., and Riley K. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 67 (2009) S328-331
117. Yang W., Wu G., Barth R.F., Swindall M.R., Bandyopadhyaya A.K., Tjarks W., Tordoff K., Moeschberger M., Sferra T.J., Binns P.J., Riley K.J., Ciesielski M.J., Fenstermaker R.A., and Wikstrand C.J. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14 (2008) 883-891
118. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., and Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14 (2008) 123-129
119. Zhang Y., Boado R.J., and Pardridge W.M. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene. Med. 5 (2003) 1039-1045
120. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., and Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10 (2004) 3667-3677
121. Zhang Y., Zhu C., and Pardridge W.M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6 (2002) 67-72